|DB01016||Glyburide||Indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone.|
|DB01586||Ursodeoxycholic acid||The drug reduces cholesterol absorption and is used to dissolve (cholesterol) gallstones in patients who want an alternative to surgery.|
|DB02659||Cholic Acid||Oral cholic acid is indicated for: treatment of bile acid synthesis disorders due to single enzyme defects; and as adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption. |
|DB00977||Ethinylestradiol||For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.|
|DB01045||Rifampicin||For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.|
|DB00091||Ciclosporin||Cyclosporine is officially approved for different conditions listed below:
* Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. For this indication, it can be used concomitantly with azathioprine and corticosteroids.
* Treatment of patients with severe active, rheumatoid arthritis when the patient no longer responds to methotrexate.
* Concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone.
* Treatment of adult nonimmunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated.[FDA label]
* Its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years old.[L5158]
* Prevention of graft rejection following bone marrow transplantation and in the treatment of graft-versus-host disease (GVHD).
* Treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and children.[F3091]
Away from all this approved and reviewed indications, cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis, blistering disorders, and connective tissue diseases.[A174085]|
|DB00845||Clofazimine||For the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.|
|DB00206||Reserpine||Foe the treatment of hypertension|
|DB00570||Vinblastine||For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.|
|DB01026||Ketoconazole||For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.|
|DB00197||Troglitazone||For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.|
|DB02703||Fusidic Acid||For the treatment of bacterial infections.|
|DB00559||Bosentan||Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).|
|DB06290||Simeprevir||Indicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: typically in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis.
Resistance: Reduced susceptibility to simeprevir was most commonly associated with the viral NS3 Q80K polymorphism. Amino acid substitutions at NS3 positions S122, R155 and/or D168 are also shown to reduce susceptibility to simeprevir in genotype 1a/b patients.
|DB12070||Letermovir||For use in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT) [FDA Label].|
|DB00396||Progesterone||For progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.|
|DB00932||Tipranavir||For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.|
Clotrimazole topical cream is indicated for the topical treatment of the following dermal infections [F3088], [F3121]:
Tinea pedis, tinea cruris, and tinea corporis due to _Trichophyton rubrum_, _Trichophyton mentagrophytes_, _Epidermophyton floccosum_
Candidiasis due to _Candida albicans_
Tinea versicolor due to _Malassezia furfur_
Diaper rash infected by _Candida albicans_
In some preparations, clotrimazole may be combined with betamethasone dipropionate, a corticosteroid [F3121].
The oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis [FDA label]. It is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation [FDA label]. Troche preparations are not indicated for the treatment of any systemic mycoses [FDA label].|
|DB09078||Lenvatinib||Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.|
|DB00477||Chlorpromazine||For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.|
|DB00501||Cimetidine||For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.|
|DB01229||Paclitaxel||Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.|
|DB00908||Quinidine||For the treatment of ventricular pre-excitation and cardiac dysrhythmias|
|DB00675||Tamoxifen||Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ. |
|DB00661||Verapamil||For the treatment of hypertension, angina, and cluster headache prophylaxis.|
|DB02123||Glycochenodeoxycholic Acid||Not Available|
Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below [FDA label]:
**Upper respiratory tract infections** of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) [FDA label].
**Lower-respiratory tract infections** of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes [FDA label].
**Pertussis (whooping cough)** caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals [FDA label].
**Respiratory tract infections** due to Mycoplasma pneumoniae [FDA label].
**Legionnaires’ Disease** caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires’ Disease [FDA label].
**Diphtheria**: Infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers [FDA label].
**Skin and skin structure infections** of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment) [FDA label].
**Erythrasma**: In the treatment of infections due to Corynebacterium minutissimum [FDA label].
**Intestinal amebiasis** caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents [FDA label].
**Acute pelvic inflammatory disease** caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months [FDA label].
**Syphilis** caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy [FDA label].
**Chlamydia trachomatis**: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis [FDA label].
**Nongonnoconnal urethritis**: When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum [FDA label].